Science Talk

With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow them to tell some of the stories behind the science. We try to put our discoveries in a wider scientific context, and give an idea of how our science is actually done. We also give you the view from the ICR of important developments in the wider world of cancer research.

01/06/23 - by

ASCO-AM23-Desktop-Logo

From 2-6 June many scientists from The Institute of Cancer Research, London, will join a global forum of world-leading scientists and oncologists at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

A global highlight of the cancer research calendar, ASCO sees the latest, practice-changing results from major phase III trials presented alongside exciting early phase trial results, translational research, and insightful commentary on all aspects of oncology.

This year’s theme is Partnering with Patients: The Cornerstone of Cancer Care and Research and the meeting will focus on better, more equitable cancer care, and the importance of meaningful relationships between oncologists and patients.

Keep reading for a summary of studies being presented by researchers from the ICR and our partners The Royal Marsden NHS Foundation Trust at ASCO 2023. 

To access the full programme with specific timings and locations visit the ASCO website.

Presentations

Friday 2 June

Oral presentations:

  • Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.
    Nicholas Turner
    Oral abstract number: 502
    14:45

Saturday 3 June

Poster presentations:

  • A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Christina Guo
    Abstract: TPS5105
    Poster Bd #: 195b
    08:00

  • Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
    Juanita Lopez
    Abstract: 2044
    Poster Bd #: 401
    13:15

  • Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).
    Shane H Zaidi
    Abstract: 11552
    Poster Bd #: 486
    13:15

  • The Man Van: Mobile targeted case finding for prostate cancer.
    Masood Moghul
    Abstract: 6522
    Poster Bd #: 14
    13:15

  • CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed.
    Abhijit Pal
    Abstract: 6560
    Poster Bd #: 52
    13:15

  • Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
    Robin Jones
    Abstract: 11524
    Poster Bd #: 458
    16:30

Sunday 4 June

Poster presentations:

  • Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
    Anna Minchom
    Abstract: 9126
    Poster Bd #: 114
    08:00

  • Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
    Alicia Okines
    Abstract: TPS1111
    Poster Bd #: 332a
    08:00

Monday 5 June

Oral presentations:

Poster presentations:

  • A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
    Kevin Harrington
    Abstract: TPS6106
    Poster Bd #: 95b
    13:15

  • Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.
    Fernando Carceller
    Abstract: 10020
    Poster Bd #: 326
    16:30

  • Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
    Susana Banerjee
    Abstract: 5515
    Poster Bd #: 210
    16:30

Join the conversation on social media with the hashtag #ASCO23.

Read more news and stories from the ASCO Annual Meeting.

ASCO Annual Meeting